Endograft use in the femoral and popliteal arteries

Saxon, Richard R.; Coffman, Jeanine M.; Gooding, Justin M.; Ponec, Donald

doi:10.1053/j.tvir.2004.01.005

Cited by 26 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 For the management of femoralepopliteal atherosclerotic disease with a suitable above-the-knee (AK) popliteal landing zone, multiple studies have now demonstrated that polytetrafluoroethylene (PTFE)-covered stent-grafts offer good short-and long-term primary and secondary patency rates. [2][3][4][5][6][7][8][9][10][11] Patency rates of PTFE stent-grafts in these studies are equivalent to those found in analyses of femoralepopliteal bypass surgery using conventional PTFE grafts. [12][13][14][15] A prospective, randomized controlled trial comparing PTFE stent-grafts and PTFE bypass grafts demonstrated equivalent patency at 1 and 2 years.…”

supporting

confidence: 56%

See 1 more Smart Citation

Traitement des occlusions proximales de l’artère fémorale superficielle par endartériectomie à ciel ouvert et angioplastie fémoro-poplitée endovasculaire avec stent

Hayes

Dougherty

Calligaro

2011

Annales de Chirurgie Vasculaire

View full text Add to dashboard Cite

supporting

confidence: 56%

“…The design and potential benefits of the Viabahn stent-graft have been previously described. 6 We lined the entire angioplasty site, with the proximal stent ending just above the SFA endarterectomy endpoint but well below the groin crease. We postdilated the entire length of all the deployed stent-grafts and stents.…”

Section: Methodsmentioning

confidence: 99%

Traitement des occlusions proximales de l’artère fémorale superficielle par endartériectomie à ciel ouvert et angioplastie fémoro-poplitée endovasculaire avec stent

Hayes

Dougherty

Calligaro

2011

Annales de Chirurgie Vasculaire

View full text Add to dashboard Cite

“…[77][78][79][80][81][82] However, the early and midterm outcomes with the Hemobahn stent-graft seem to be competitive with prosthetic surgical bypass. 31,[83][84][85][86][87][88][89][90] It should be noted that these are relatively small series of patients, and the utility of ePTFE in TASC C and D disease is unclear. A comparative study between the endovascular placement of the Hemobahn stent-graft and surgical bypass would help provide solid evidence-based support for use of this technology.…”

Section: Covered Stentsmentioning

confidence: 99%

An Update on Endovascular Therapy of the Lower Extremities

Bates

AbuRahma

2004

J Endovasc Ther

View full text Add to dashboard Cite

ࡗ ࡗConsiderable advances have been made over the last decade in percutaneous technology for treatment of atherosclerotic diseases in the iliac, femoropopliteal, and distal tibioperoneal arteries. While treatment strategies are well defined in the iliofemoral segment, where angioplasty and stenting perform well in appropriately selected lesions, the search for a durable transcatheter therapy for femoropopliteal and distal occlusive disease continues. The spectrum of treatment alternatives to angioplasty ranges from transcatheter plaque excision to laser ablation, rotational atherectomy, cryoplasty, brachytherapy, and stenting. We review in this article the status of percutaneous endovascular techniques for the treatment of lower extremity vascular occlusive disease.

show abstract

“…[45][46][47][48][49][50][51][52][53] Recently, the TCT (Trans Catheter Therapeutics) 2006 meeting presented promising single-centre registry data on the 1-year patency of the Viabahn TM (WL Gore and Associates, Inc.) application in long native SFA lesions and on in-stent lesions too being 90% and 65%, respectively. 54,55 Moreover, Saxon et al 56 reported a 79% primary patency rate and 93% secondary patency rate at the 4-year follow-up for lesions of an average length Ͼ10 cm, using Hemobahn or Viabahn stent grafts. Another potential indication for the application of this technology might be the treatment of femoro-popliteal aneurysms.…”

Section: Endograftsmentioning

confidence: 99%

Current state of endovascular treatment of femoro-popliteal artery disease

Zeller

2007

Vasc Med

114

View full text Add to dashboard Cite

Considerable advances have been made over the last decade in percutaneous technology for the treatment of atherosclerotic diseases in the femoro-popliteal arteries. While treatment strategies are well defined in the iliac segment, where angioplasty and stenting perform well in appropriately selected lesions, the search for a durable transcatheter therapy for femoro-popliteal lesions continues. Whereas balloon angioplasty (PTA) is the accepted therapy for short lesions, long diffuse lesions are still recommended for surgical treatment. However, attractive new technologies ranging from transcatheter plaque excision to laser ablation, rotational atherectomy, cryoplasty, brachytherapy, and placement of drug-eluting stents to simple angioplasty with drug-coated balloons may have the potential to replace femoro-popliteal bypass surgery as a treatment of choice for complex lesions. This article reviews the status of percutaneous endovascular techniques for the treatment of femoro-popliteal artery occlusive disease.Key words: angioplasty; percutaneous intervention; peripheral occlusive disease; popliteal artery; stent; superficial femoral artery Albert-Ludwigs-University Freiburg, Freiburg, Germany and Department of Angiology, Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany Address for correspondence: Thomas Zeller, Abteilung Angiologie, Herz-Zentrum Bad Krozingen, Südring 15, D-79189 Bad Krozingen, Germany. Tel: ϩ49 7633/4020; Fax: ϩ49 7633/402-8208; E-mail: thomas.zeller@herzzentrum.de defined as target lesion revascularization (TLR). If another lesion at the target vessel site but not the index lesion itself needs to be treated during follow-up this intervention is defined as target vessel revascularization (TVR). Superficial femoral artery and popliteal artery diseaseThe superficial femoral artery (SFA) extending to the proximal popliteal artery segment is the most commonly diseased vasculature. More than 50% of all PAD cases involve the SFA and popliteal artery. Femoro-popliteal disease is often characterized by long, diffuse lesions, long occlusions (as opposed to mild focal stenoses). The unique slow-flow and highresistance environment in the femoro-popliteal region creates a milieu that seems to increase the prevalence of de novo disease. The same issues that lead to accumulation of plaque within the femoro-popliteal region likely amplify the response to injury and may explain the high incidence of restenosis following traditional angioplasty. 9 Femoro-popliteal occlusive disease is still the Achilles heel of the vascular specialist.The durability of femoro-popliteal intervention can be predicted by the pre-procedural angiographic characteristics of the target lesion. The TASC I and the updated TASC II document 6 divided the femoropopliteal lesions into four categories (Table 1). TASC A lesions are more suitable for endovascular procedures, whereas surgery is recommended for TASC D lesions. The TASC document clearly states that it takes more evidence to make firm recommendations about the role of an...

show abstract

Endograft use in the femoral and popliteal arteries

Cited by 26 publications

References 22 publications

Traitement des occlusions proximales de l’artère fémorale superficielle par endartériectomie à ciel ouvert et angioplastie fémoro-poplitée endovasculaire avec stent

Traitement des occlusions proximales de l’artère fémorale superficielle par endartériectomie à ciel ouvert et angioplastie fémoro-poplitée endovasculaire avec stent

An Update on Endovascular Therapy of the Lower Extremities

Current state of endovascular treatment of femoro-popliteal artery disease

Contact Info

Product

Resources

About